Prophylactic Effects of Interleukin-2 Receptor Antagonists against Graft-versus-Host Disease Following Unrelated Donor Peripheral Blood Stem Cell Transplantation

Schlenk, 2010, Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A, J Clin Oncol, 28, 4642, 10.1200/JCO.2010.28.6856 Gupta, 2011, Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns, Blood, 117, 2307, 10.1182/blood-2010-10-265603 Basara, 2005, Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group, Bone Marrow Transplant, 35, 1011, 10.1038/sj.bmt.1704957 Bacigalupo, 2001, Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, 98, 2942, 10.1182/blood.V98.10.2942 Koreth, 2008, Current and future approaches for control of graft-versus-host disease, Expert Rev Hematol, 1, 111, 10.1586/17474086.1.1.111 Bacigalupo, 2002, Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants, Biol Blood Marrow Transplant, 8, 656, 10.1053/bbmt.2002.v8.abbmt080656 Bacigalupo, 2005, Antithymocyte globulin for prevention of graft-versus-host disease, Curr Opin Hematol, 12, 457, 10.1097/01.moh.0000183726.42063.ec Brennan, 2006, Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation, N Engl J Med, 355, 1967, 10.1056/NEJMoa060068 Sageshima, 2009, Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation, Biologics, 3, 319 Mattei, 2007, Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy, J Heart Lung Transplant, 26, 693, 10.1016/j.healun.2007.05.002 McKeage, 2010, Basiliximab: a review of its use as induction therapy in renal transplantation, BioDrugs, 24, 55, 10.2165/11203990-000000000-00000 Yao, 2006, A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children, Health Technol Assess, 10, 10.3310/hta10490 Chapman, 2003, Basiliximab: a review of its use as induction therapy in renal transplantation, Drugs, 63, 2803, 10.2165/00003495-200363240-00009 Berger, 2008, Innovative approaches to treat steroid-resistant or steroid refractory GVHD, Bone Marrow Transplant, 42, S101, 10.1038/bmt.2008.294 Depper, 1983, Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation, J Immunol, 131, 690, 10.4049/jimmunol.131.2.690 Miano, 2009, Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience, Bone Marrow Transplant, 43, 423, 10.1038/bmt.2008.331 Funke, 2006, Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist, Bone Marrow Transplant, 37, 961, 10.1038/sj.bmt.1705306 Wawer, 2004, Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD, Klin Padiatr, 216, 169, 10.1055/s-2004-822630 Ji, 2005, Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies, Bone Marrow Transplant, 36, 349, 10.1038/sj.bmt.1705046 Shamsi, 2005, Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody Daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report, J Pak Med Assoc, 55, 454 Chen, 2003, Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion, Exp Hematol, 31, 1019, 10.1016/S0301-472X(03)00228-5 Maschan, 2004, Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors, Bone Marrow Transplant, 34, 305, 10.1038/sj.bmt.1704580 Shigematsu, 2008, Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia, Biol Blood Marrow Transplant, 14, 568, 10.1016/j.bbmt.2008.02.018 Kern, 2003, Early blast clearance by remission induction chemotherapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML cooperative group (AMLCG) 1992 trial, Blood, 101, 64, 10.1182/blood-2002-02-0532 Grimwade, 1998, The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRCAML10 trial—The Medical Research Council Adult and Children’s Leukaemia Working Parties, Blood, 92, 2322, 10.1182/blood.V92.7.2322 Slovak, 2000, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study, Blood, 96, 4075, 10.1182/blood.V96.13.4075 Schoch, 2001, Patients with denovo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients, Br J Haematol, 112, 118, 10.1046/j.1365-2141.2001.02511.x Appelbaum, 2001, Who should be transplanted for AML, Leukemia, 15, 680, 10.1038/sj.leu.2402074 Schoch, 2004, Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1092 patients with de novo AML, Leukemia, 18, 120, 10.1038/sj.leu.2403187 Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 2079, 10.1182/blood.V89.6.2079 Antin, 2001, Biol Blood Marrow Transplant, 7, 473, 10.1053/bbmt.2001.v7.pm11669214 Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825 Sullivan, 1999, Graft-versus-host disease, 515 Grewal, 2003, Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?, Blood, 101, 4233, 10.1182/blood-2002-08-2510 Duggan, 2002, Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis, Bone Marrow Transplant, 30, 681, 10.1038/sj.bmt.1703674 Finke, 2009, Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, 10, 855, 10.1016/S1470-2045(09)70225-6 Seggewiss, 2010, Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update, Blood, 115, 3861, 10.1182/blood-2009-12-234096 Campara, 2010, Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation, Expert Opin Biol Ther, 10, 959, 10.1517/14712598.2010.485187 Couriel, 2004, Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management, Cancer, 101, 1936, 10.1002/cncr.20613 Salvana, 2009, Infectious complications associated with monoclonal antibodies and related small molecules, Clin Microbiol Rev, 22, 274, 10.1128/CMR.00040-08 Pidala, 2011, ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation, Biol Blood Marrow Transplant, 10.1016/j.bbmt.2010.12.705 Blaise, 1995, Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis, Lancet, 345, 1144, 10.1016/S0140-6736(95)90978-8 Schmidt-Hieber, 2005, Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease, Br J Haematol, 130, 568, 10.1111/j.1365-2141.2005.05631.x Lu, 2006, Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation, Blood, 107, 3065, 10.1182/blood-2005-05-2146 Kandus, 2010, Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study, Transplantation, 89, 1022, 10.1097/TP.0b013e3181d02496 Naderi, 2009, The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study, Transplant Proc, 41, 2768, 10.1016/j.transproceed.2009.06.180 Vega, 2008, Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation, Rev Invest Clin, 60, 82 Pham, 2005, Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection, Transplant Proc, 37, 899, 10.1016/j.transproceed.2004.12.079 Lin, 2006, Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study, Clin Transplant, 20, 325, 10.1111/j.1399-0012.2005.00488.x Hershberger, 2005, Daclizumab to prevent rejection after cardiac transplantation, N Engl J Med, 352, 2705, 10.1056/NEJMoa032953 Kircher, 2003, Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies, Clin Exp Immunol, 134, 426, 10.1111/j.1365-2249.2003.02324.x